Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.

The global market for Companion Cancer Diagnostics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Companion Cancer Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Companion Cancer Diagnostics by region & country, by Type, and by Application.

The Companion Cancer Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Cancer Diagnostics.

Market Segmentation

Scope of Companion Cancer Diagnostics - Market Report

Report Metric	Details
Report Name	Companion Cancer Diagnostics - Market
CAGR	5%
Segment by Type:	Breast Cancer Lung Cancer Colorectal Cancer Melanoma Gastric Cancer
Segment by Application	Pharmaceutical & Biopharmaceutical Companies Reference Laboratories CROs Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	F. Hoffmann-La Roche, Agilent Technologies, QIAGEN, Abbott Laboratories, Almac Group, Danaher Corporation, bioMérieuxSA, Myriad Genetics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Companion Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Companion Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Companion Cancer Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Companion Cancer Diagnostics - Market report?

Ans: The main players in the Companion Cancer Diagnostics - Market are F. Hoffmann-La Roche, Agilent Technologies, QIAGEN, Abbott Laboratories, Almac Group, Danaher Corporation, bioMérieuxSA, Myriad Genetics

What are the Application segmentation covered in the Companion Cancer Diagnostics - Market report?

Ans: The Applications covered in the Companion Cancer Diagnostics - Market report are Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Others

What are the Type segmentation covered in the Companion Cancer Diagnostics - Market report?

Ans: The Types covered in the Companion Cancer Diagnostics - Market report are Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gastric Cancer

1 Market Overview

1.1 Companion Cancer Diagnostics Product Introduction

1.2 Global Companion Cancer Diagnostics Market Size Forecast

1.3 Companion Cancer Diagnostics Market Trends & Drivers

1.3.1 Companion Cancer Diagnostics Industry Trends

1.3.2 Companion Cancer Diagnostics Market Drivers & Opportunity

1.3.3 Companion Cancer Diagnostics Market Challenges

1.3.4 Companion Cancer Diagnostics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Companion Cancer Diagnostics Players Revenue Ranking (2023)

2.2 Global Companion Cancer Diagnostics Revenue by Company (2019-2024)

2.3 Key Companies Companion Cancer Diagnostics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Companion Cancer Diagnostics Product Offered

2.5 Key Companies Time to Begin Mass Production of Companion Cancer Diagnostics

2.6 Companion Cancer Diagnostics Market Competitive Analysis

2.6.1 Companion Cancer Diagnostics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Companion Cancer Diagnostics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Cancer Diagnostics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Breast Cancer

3.1.2 Lung Cancer

3.1.3 Colorectal Cancer

3.1.4 Melanoma

3.1.5 Gastric Cancer

3.2 Global Companion Cancer Diagnostics Sales Value by Type

3.2.1 Global Companion Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Companion Cancer Diagnostics Sales Value, by Type (2019-2030)

3.2.3 Global Companion Cancer Diagnostics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Pharmaceutical & Biopharmaceutical Companies

4.1.2 Reference Laboratories

4.1.3 CROs

4.1.4 Others

4.2 Global Companion Cancer Diagnostics Sales Value by Application

4.2.1 Global Companion Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Companion Cancer Diagnostics Sales Value, by Application (2019-2030)

4.2.3 Global Companion Cancer Diagnostics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Companion Cancer Diagnostics Sales Value by Region

5.1.1 Global Companion Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Companion Cancer Diagnostics Sales Value by Region (2019-2024)

5.1.3 Global Companion Cancer Diagnostics Sales Value by Region (2025-2030)

5.1.4 Global Companion Cancer Diagnostics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Companion Cancer Diagnostics Sales Value, 2019-2030

5.2.2 North America Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Companion Cancer Diagnostics Sales Value, 2019-2030

5.3.2 Europe Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Companion Cancer Diagnostics Sales Value, 2019-2030

5.4.2 Asia Pacific Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Companion Cancer Diagnostics Sales Value, 2019-2030

5.5.2 South America Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Companion Cancer Diagnostics Sales Value, 2019-2030

5.6.2 Middle East & Africa Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Companion Cancer Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Companion Cancer Diagnostics Sales Value

6.3 United States

6.3.1 United States Companion Cancer Diagnostics Sales Value, 2019-2030

6.3.2 United States Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Companion Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Companion Cancer Diagnostics Sales Value, 2019-2030

6.4.2 Europe Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Companion Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Companion Cancer Diagnostics Sales Value, 2019-2030

6.5.2 China Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Companion Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Companion Cancer Diagnostics Sales Value, 2019-2030

6.6.2 Japan Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Companion Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Companion Cancer Diagnostics Sales Value, 2019-2030

6.7.2 South Korea Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Companion Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Companion Cancer Diagnostics Sales Value, 2019-2030

6.8.2 Southeast Asia Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Companion Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Companion Cancer Diagnostics Sales Value, 2019-2030

6.9.2 India Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Companion Cancer Diagnostics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 F. Hoffmann-La Roche

7.1.1 F. Hoffmann-La Roche Profile

7.1.2 F. Hoffmann-La Roche Main Business

7.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Products, Services and Solutions

7.1.4 F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.1.5 F. Hoffmann-La Roche Recent Developments

7.2 Agilent Technologies

7.2.1 Agilent Technologies Profile

7.2.2 Agilent Technologies Main Business

7.2.3 Agilent Technologies Companion Cancer Diagnostics Products, Services and Solutions

7.2.4 Agilent Technologies Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.2.5 Agilent Technologies Recent Developments

7.3 QIAGEN

7.3.1 QIAGEN Profile

7.3.2 QIAGEN Main Business

7.3.3 QIAGEN Companion Cancer Diagnostics Products, Services and Solutions

7.3.4 QIAGEN Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.3.5 Abbott Laboratories Recent Developments

7.4 Abbott Laboratories

7.4.1 Abbott Laboratories Profile

7.4.2 Abbott Laboratories Main Business

7.4.3 Abbott Laboratories Companion Cancer Diagnostics Products, Services and Solutions

7.4.4 Abbott Laboratories Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.4.5 Abbott Laboratories Recent Developments

7.5 Almac Group

7.5.1 Almac Group Profile

7.5.2 Almac Group Main Business

7.5.3 Almac Group Companion Cancer Diagnostics Products, Services and Solutions

7.5.4 Almac Group Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.5.5 Almac Group Recent Developments

7.6 Danaher Corporation

7.6.1 Danaher Corporation Profile

7.6.2 Danaher Corporation Main Business

7.6.3 Danaher Corporation Companion Cancer Diagnostics Products, Services and Solutions

7.6.4 Danaher Corporation Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.6.5 Danaher Corporation Recent Developments

7.7 bioMérieuxSA

7.7.1 bioMérieuxSA Profile

7.7.2 bioMérieuxSA Main Business

7.7.3 bioMérieuxSA Companion Cancer Diagnostics Products, Services and Solutions

7.7.4 bioMérieuxSA Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.7.5 bioMérieuxSA Recent Developments

7.8 Myriad Genetics

7.8.1 Myriad Genetics Profile

7.8.2 Myriad Genetics Main Business

7.8.3 Myriad Genetics Companion Cancer Diagnostics Products, Services and Solutions

7.8.4 Myriad Genetics Companion Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.8.5 Myriad Genetics Recent Developments

8 Industry Chain Analysis

8.1 Companion Cancer Diagnostics Industrial Chain

8.2 Companion Cancer Diagnostics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Companion Cancer Diagnostics Sales Model

8.5.2 Sales Channel

8.5.3 Companion Cancer Diagnostics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Companion Cancer Diagnostics Market Trends

Table 2. Companion Cancer Diagnostics Market Drivers & Opportunity

Table 3. Companion Cancer Diagnostics Market Challenges

Table 4. Companion Cancer Diagnostics Market Restraints

Table 5. Global Companion Cancer Diagnostics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Companion Cancer Diagnostics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Companion Cancer Diagnostics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Companion Cancer Diagnostics Product Type

Table 9. Key Companies Time to Begin Mass Production of Companion Cancer Diagnostics

Table 10. Global Companion Cancer Diagnostics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Cancer Diagnostics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Companion Cancer Diagnostics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Companion Cancer Diagnostics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Companion Cancer Diagnostics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Companion Cancer Diagnostics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Companion Cancer Diagnostics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Companion Cancer Diagnostics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Companion Cancer Diagnostics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Companion Cancer Diagnostics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Companion Cancer Diagnostics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Companion Cancer Diagnostics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Companion Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Companion Cancer Diagnostics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Companion Cancer Diagnostics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Companion Cancer Diagnostics Sales Value by Region (2019-2024) & (%)

Table 27. Global Companion Cancer Diagnostics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Companion Cancer Diagnostics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Companion Cancer Diagnostics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Companion Cancer Diagnostics Sales Value, (2025-2030) & (US$ Million)

Table 31. F. Hoffmann-La Roche Basic Information List

Table 32. F. Hoffmann-La Roche Description and Business Overview

Table 33. F. Hoffmann-La Roche Companion Cancer Diagnostics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Companion Cancer Diagnostics Business of F. Hoffmann-La Roche (2019-2024)

Table 35. F. Hoffmann-La Roche Recent Developments

Table 36. Agilent Technologies Basic Information List

Table 37. Agilent Technologies Description and Business Overview

Table 38. Agilent Technologies Companion Cancer Diagnostics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Companion Cancer Diagnostics Business of Agilent Technologies (2019-2024)

Table 40. Agilent Technologies Recent Developments

Table 41. QIAGEN Basic Information List

Table 42. QIAGEN Description and Business Overview

Table 43. QIAGEN Companion Cancer Diagnostics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Companion Cancer Diagnostics Business of QIAGEN (2019-2024)

Table 45. QIAGEN Recent Developments

Table 46. Abbott Laboratories Basic Information List

Table 47. Abbott Laboratories Description and Business Overview

Table 48. Abbott Laboratories Companion Cancer Diagnostics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Companion Cancer Diagnostics Business of Abbott Laboratories (2019-2024)

Table 50. Abbott Laboratories Recent Developments

Table 51. Almac Group Basic Information List

Table 52. Almac Group Description and Business Overview

Table 53. Almac Group Companion Cancer Diagnostics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Companion Cancer Diagnostics Business of Almac Group (2019-2024)

Table 55. Almac Group Recent Developments

Table 56. Danaher Corporation Basic Information List

Table 57. Danaher Corporation Description and Business Overview

Table 58. Danaher Corporation Companion Cancer Diagnostics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Companion Cancer Diagnostics Business of Danaher Corporation (2019-2024)

Table 60. Danaher Corporation Recent Developments

Table 61. bioMérieuxSA Basic Information List

Table 62. bioMérieuxSA Description and Business Overview

Table 63. bioMérieuxSA Companion Cancer Diagnostics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Companion Cancer Diagnostics Business of bioMérieuxSA (2019-2024)

Table 65. bioMérieuxSA Recent Developments

Table 66. Myriad Genetics Basic Information List

Table 67. Myriad Genetics Description and Business Overview

Table 68. Myriad Genetics Companion Cancer Diagnostics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Companion Cancer Diagnostics Business of Myriad Genetics (2019-2024)

Table 70. Myriad Genetics Recent Developments

Table 71. Key Raw Materials Lists

Table 72. Raw Materials Key Suppliers Lists

Table 73. Companion Cancer Diagnostics Downstream Customers

Table 74. Companion Cancer Diagnostics Distributors List

Table 75. Research Programs/Design for This Report

Table 76. Key Data Information from Secondary Sources

Table 77. Key Data Information from Primary Sources

Table 78. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Companion Cancer Diagnostics Product Picture

Figure 2. Global Companion Cancer Diagnostics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Companion Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 4. Companion Cancer Diagnostics Report Years Considered

Figure 5. Global Companion Cancer Diagnostics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Companion Cancer Diagnostics Revenue in 2023

Figure 7. Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Breast Cancer Picture

Figure 9. Lung Cancer Picture

Figure 10. Colorectal Cancer Picture

Figure 11. Melanoma Picture

Figure 12. Gastric Cancer Picture

Figure 13. Global Companion Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Companion Cancer Diagnostics Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Pharmaceutical & Biopharmaceutical Companies

Figure 16. Product Picture of Reference Laboratories

Figure 17. Product Picture of CROs

Figure 18. Product Picture of Others

Figure 19. Global Companion Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 20. Global Companion Cancer Diagnostics Sales Value Market Share by Application, 2023 & 2030

Figure 21. North America Companion Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 22. North America Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 23. Europe Companion Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 24. Europe Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 25. Asia Pacific Companion Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 26. Asia Pacific Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 27. South America Companion Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 28. South America Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 29. Middle East & Africa Companion Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 30. Middle East & Africa Companion Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 31. Key Countries/Regions Companion Cancer Diagnostics Sales Value (%), (2019-2030)

Figure 32. United States Companion Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 33. United States Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 34. United States Companion Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 35. Europe Companion Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 36. Europe Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 37. Europe Companion Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 38. China Companion Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 39. China Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 40. China Companion Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 41. Japan Companion Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 42. Japan Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 43. Japan Companion Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 44. South Korea Companion Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 45. South Korea Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 46. South Korea Companion Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 47. Southeast Asia Companion Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 48. Southeast Asia Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 49. Southeast Asia Companion Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 50. India Companion Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 51. India Companion Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 52. India Companion Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 53. Companion Cancer Diagnostics Industrial Chain

Figure 54. Companion Cancer Diagnostics Manufacturing Cost Structure

Figure 55. Channels of Distribution (Direct Sales, and Distribution)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-26D6003

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Global Chemotherapy Chairs Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-26D13514

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Drugs for Non-Small Cell Lung Cancer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-33S12067

Fri Oct 11 00:00:00 UTC 2024

Add to Cart

Anti-Oral Mucositis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-5V5924

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Companion Cancer Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: October 2024

Report Code: QYRE-Auto-19D5863

Companion Cancer Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Companion Cancer Diagnostics - Market Size

Companion Cancer Diagnostics - Market

Report Scope

Scope of Companion Cancer Diagnostics - Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Companion Cancer Diagnostics - Market report?

What are the Application segmentation covered in the Companion Cancer Diagnostics - Market report?

What are the Type segmentation covered in the Companion Cancer Diagnostics - Market report?

FEATURED COMPANIES

RELATED REPORTS